SNDX
Price
$15.68
Change
+$0.65 (+4.32%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
1.29B
46 days until earnings call
VRTX
Price
$385.80
Change
+$3.93 (+1.03%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
97.91B
33 days until earnings call
Interact to see
Advertisement

SNDX vs VRTX

Header iconSNDX vs VRTX Comparison
Open Charts SNDX vs VRTXBanner chart's image
Syndax Pharmaceuticals
Price$15.68
Change+$0.65 (+4.32%)
Volume$60.76K
Capitalization1.29B
Vertex Pharmaceuticals
Price$385.80
Change+$3.93 (+1.03%)
Volume$28.57K
Capitalization97.91B
SNDX vs VRTX Comparison Chart in %
Loading...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SNDX vs. VRTX commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SNDX is a Hold and VRTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (SNDX: $15.03 vs. VRTX: $381.87)
Brand notoriety: SNDX and VRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SNDX: 100% vs. VRTX: 136%
Market capitalization -- SNDX: $1.29B vs. VRTX: $97.91B
SNDX [@Biotechnology] is valued at $1.29B. VRTX’s [@Biotechnology] market capitalization is $97.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SNDX’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 0 green FA rating(s).

  • SNDX’s FA Score: 1 green, 4 red.
  • VRTX’s FA Score: 0 green, 5 red.
According to our system of comparison, VRTX is a better buy in the long-term than SNDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SNDX’s TA Score shows that 5 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s).

  • SNDX’s TA Score: 5 bullish, 4 bearish.
  • VRTX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than SNDX.

Price Growth

SNDX (@Biotechnology) experienced а -2.72% price change this week, while VRTX (@Biotechnology) price change was -1.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +9.50%, and the average quarterly price growth was +52.01%.

Reported Earning Dates

SNDX is expected to report earnings on Nov 11, 2025.

VRTX is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($97.9B) has a higher market cap than SNDX($1.3B). SNDX YTD gains are higher at: 13.691 vs. VRTX (-5.173). VRTX has higher annual earnings (EBITDA): 4.59B vs. SNDX (-314.25M). VRTX has more cash in the bank: 6.38B vs. SNDX (469M). SNDX has less debt than VRTX: SNDX (1.68M) vs VRTX (1.53B). VRTX has higher revenues than SNDX: VRTX (11.4B) vs SNDX (77.9M).
SNDXVRTXSNDX / VRTX
Capitalization1.3B97.9B1%
EBITDA-314.25M4.59B-7%
Gain YTD13.691-5.173-265%
P/E RatioN/A27.16-
Revenue77.9M11.4B1%
Total Cash469M6.38B7%
Total Debt1.68M1.53B0%
FUNDAMENTALS RATINGS
SNDX vs VRTX: Fundamental Ratings
SNDX
VRTX
OUTLOOK RATING
1..100
8057
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
10054
SMR RATING
1..100
9942
PRICE GROWTH RATING
1..100
4564
P/E GROWTH RATING
1..100
444
SEASONALITY SCORE
1..100
5055

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRTX's Valuation (72) in the Biotechnology industry is in the same range as SNDX (83). This means that VRTX’s stock grew similarly to SNDX’s over the last 12 months.

VRTX's Profit vs Risk Rating (54) in the Biotechnology industry is somewhat better than the same rating for SNDX (100). This means that VRTX’s stock grew somewhat faster than SNDX’s over the last 12 months.

VRTX's SMR Rating (42) in the Biotechnology industry is somewhat better than the same rating for SNDX (99). This means that VRTX’s stock grew somewhat faster than SNDX’s over the last 12 months.

SNDX's Price Growth Rating (45) in the Biotechnology industry is in the same range as VRTX (64). This means that SNDX’s stock grew similarly to VRTX’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is somewhat better than the same rating for VRTX (44). This means that SNDX’s stock grew somewhat faster than VRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SNDXVRTX
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
48%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
37%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend about 1 month ago
59%
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 3 days ago
41%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
29%
View a ticker or compare two or three
Interact to see
Advertisement
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AWSIX17.96N/A
N/A
Invesco Global Core Equity R5
TVOCX37.38N/A
N/A
Touchstone Small Cap Value C
WEUSX14.84N/A
N/A
SEI World Equity Ex-US A (SIIT)
MSDMX15.11N/A
N/A
Morgan Stanley Emerging Mkt ex China R6
RLGYX11.58N/A
N/A
Russell Inv Global Equity Y

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+0.13%
REPL - SNDX
51%
Loosely correlated
-2.64%
CGON - SNDX
49%
Loosely correlated
-0.55%
NRIX - SNDX
47%
Loosely correlated
-4.25%
NUVL - SNDX
47%
Loosely correlated
-2.54%
XENE - SNDX
47%
Loosely correlated
-0.19%
More

VRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with NEVPF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRTX
1D Price
Change %
VRTX100%
+1.39%
NEVPF - VRTX
47%
Loosely correlated
N/A
SNDX - VRTX
41%
Loosely correlated
+0.13%
FOLD - VRTX
35%
Loosely correlated
-0.36%
IDYA - VRTX
34%
Loosely correlated
+0.08%
JAZZ - VRTX
34%
Loosely correlated
-1.38%
More